Responsibility in Drug Advertising Act of 2025
Sponsored By: Senator Angus King
Introduced
Summary
A three-year ban on direct-to-consumer advertising for newly approved prescription drugs would stop companies from promoting new medicines directly to the public while regulators gather more safety and value evidence. The ban covers social media, allows the Food and Drug Administration to grant a waiver in the third year if advertising shows affirmative public health value, and lets the agency extend the ban later if post-approval studies or reports identify significant safety problems.
Show full summary
- Families and patients: Exposure to promotional ads for new drugs would be limited for the first three years, so early information about new treatments is more likely to come from clinicians and regulators than from adverts.
- Drug sponsors: Companies could not run direct-to-consumer campaigns, including on social media, during that initial period unless they win a third-year waiver that demonstrates public health benefit. They also face possible renewed advertising bans if safety signals appear after approval.
- Food and Drug Administration and enforcement: The bill would require the FDA to revise advertising rules within one year and creates a specific statutory violation to help enforce the advertising restrictions under existing authorities.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Limits drug ads for newly approved drugs
If enacted, the bill would ban direct-to-consumer ads for prescription drugs for three years after FDA approval. The ban would include ads on social media. It would apply only to drugs approved on or after one year before enactment. In the third year, a drug sponsor could apply for a waiver. The Secretary could grant a waiver if advertising has an affirmative public-health value. After three years, the Secretary could prohibit ads if new evidence shows significant health harms. The bill would require FDA to update ad rules within one year. It would also make violating the new rule a specific prohibited act. The bill would not limit the FDA’s other ad powers.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Angus King
ME • I
Cosponsors
Sen. Kaine, Tim [D-VA]
VA • D
Sponsored 2/6/2025
Peter Welch
VT • D
Sponsored 2/6/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in